

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 03/104467 A1

- (15) International Patent Classification⁷: **C12N 15/86**
- (21) International Application Number: **PCT/EP03/50125**
- (22) International Filing Date: **24 April 2003 (24.04.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
PCT/NL02/00280 **25 April 2002 (25.04.2002)** **NL**
- (71) Applicant (*for all designated States except US*): **CRU-CELL HOLLAND B.V.** [NL/NL]; Archimedesweg 4, NL-2333 CN Leiden (NL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— *with international search report*
- (72) Inventors; and
(75) Inventors/Applicants (*for US only*): **VOGELS, Ronald** [NL/NL]; Van Rietlaan 4, NL-3461 HW Linschoten (NL). **BOUT, Abraham** [NL/NL]; Van Swaanswijkstraat 38, NL-2751 XL Moerkapelle (NL).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 03/104467 A1

(54) Title: **MEANS AND METHODS FOR THE PRODUCTION OF ADENOVIRUS VECTORS**

(57) Abstract: The invention relates to methods and means for the production of adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products provided by the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.

Title: Means and methods for the production of adenovirus vectors.

FIELD OF THE INVENTION

The invention relates to nucleic acid delivery vehicles and use thereof, more in particular the invention relates to
5 recombinant adenoviral vectors and the use thereof.

BACKGROUND OF THE INVENTION

To date 51 human adenovirus serotypes have been
10 identified that are subdivided into 6 subgroups (A, B, C, D, E and F) based on hemagglutination properties and sequence homology (Francki et al. 1991). The adenovirus infectious cycle is divided into an early and a late phase. In the early phase, the virus is uncoated and the genome is transported to
15 the nucleus after which the early gene regions (E1, E2, E3 and E4) become transcriptionally active. The E1 region contains two transcription regions: E1A and E1B. E1A encodes proteins that are involved in modification of the host cell cycle and activation of the other viral transcription regions
20 (reviewed by Russell. 2000). The E1B region encodes two major proteins: E1B-19K and E1B-55K, that prevent the induction of apoptosis resulting from the activity of the E1A proteins (Rao et al. 1992; Yew and Berk 1992; Shenk 1996). In addition, the E1B-55K protein is required in the late phase
25 for selective viral mRNA transport and inhibition of host protein expression (Pilder et al. 1986). E2 is also divided in two subdomains: E2A and E2B, that together encode three proteins (a DNA binding protein, a viral polymerase and a pre-terminal protein) that are all involved in replication of

the viral genome (Van der Vliet 1995). E3 is not necessary for replication *in vitro* but encodes several proteins that subvert the host defence mechanism towards viral infection (Horwitz 2001). E4 harbours at least 6 open reading frames (orf's) that encode proteins involved in several distinct functions related to viral mRNA splicing and transport, host cell mRNA transport, viral and cellular transcription and transformation (reviewed by Leppard 1997). The late proteins, necessary for formation of the viral capsids and packaging of viral genomes, are all generated from the major late transcription unit (MLTU) that becomes fully active after the onset of replication. A complex process of differential splicing and poly-adenylation gives rise to more than 15 mRNA species that share a tripartite leader sequence. The E1B-55K, E4-orf3 and E4-orf6 proteins play a pivotal role in the regulation of late viral mRNA processing and transport from the nucleus. For this process E1B-55K interacts with E4-orf6 to form a functional complex that stimulates transport of viral mRNA's to the cytoplasm, while the complex is also involved in inhibition of the transport of cellular mRNA's from the nucleus to the cytoplasm (reviewed in Leppard 1997 and 1998).

Production of E1-deleted vectors based on subgroup C serotypes Ad5 or Ad2 is achieved in E1 complementing cell lines such as 293 (Graham et al. 1970), 911 (Fallaux et al. 1996) and PER.C6™ (Fallaux et al. 1998; ECACC deposit no. 96022940). As disclosed in WO 99/55132 and WO 01/05945, vectors and cell line can be matched to avoid generation of replication competent adenoviruses through homologous recombination between adenovirus sequences in the cell line and the vector. For efficient production of replication incompetent adenoviruses derived from group C, the cell line

PER.C6^m is preferably used. Using this cell line adenovirus vectors can be matched, thereby allowing for the production of group C adenoviral vectors in the absence of replication competent adenovirus (Fallaux et al. 1998; US patent no. 5 6,033,908). However, group C vectors may not always be the ideal vehicles for direct *in vivo* applications since the infection efficiency is seriously hampered by the presence of high titers of neutralizing activity in most humans and the absence of sufficient amounts of the cellular receptor 10 (Coxsackie-adenovirus receptor, CAR) on specific primary target cells (e.g. endothelial cells, smooth muscle cells, synoviocytes, monocytes and dendritic cells). Administration of higher amounts of viruses to increase transduction may lead to increased toxicity and unpredictable clinical outcome 15 due to the variation in neutralizing titers of subjects that are treated. These limitations can be overcome by the use of other serotypes of adenoviruses. For example, the receptor binding part of a fiber of subgroup B viruses (in particular of serotype 16) when expressed on an Ad5-based vector, 20 mediated significantly increased infection of human endothelial cells and smooth muscle cells (WO 00/31285) and of human synoviocytes (WO 00/52186). The fiber of another subgroup B adenovirus, Ad35, is most efficient in mediating infection of human monocytes and dendritic cells (WO 25 00/03029). Furthermore, Ad35 has been identified as a virus to which the vast majority of the human population has no neutralizing activity (WO 00/70071).

There is a generally felt need in the art to develop technology that has broader serotype utility. A particular 30 problem is the lack of suitable packaging cell lines for these other serotypes. Packaging cell lines for Ad5 vectors typically comprises E1 encoded proteins derived from

adenovirus serotype 5. Examples of such 'standard' packaging cell lines are 293, 911 and PER.C6™. Attempts to produce vectors derived from other serotypes on these standard packaging cell lines have proven arduous if not unsuccessful.

- 5 Occasionally, some production is seen, depending on the particular serotype used. However, the yields of recombinant adenovirus vectors derived from adenovirus subgroups other than subgroup C, produced on cell lines transformed and immortalized by E1 from Ad5, is poor. In a paper by
- 10 Abrahamsen et al. (1997), improved plaque purification of an E1A-deleted adenovirus serotype 7 vector (subgroup B) was observed on 293 cells comprising E4-orf6 derived from adenovirus serotype 5, as compared to 293 cells lacking the E4-orf6 sequence from Ad5. However, a problem was encountered
- 15 with the stability of the vector as unexpected recombinations were observed in plaque-purified stocks. An additional problem was encountered with wild type adenovirus virus contamination during production. Moreover, for large-scale production of adenoviruses it is not useful to co-transfect
- 20 E4-orf6 to obtain titers that are high enough for application. One option for growing such adenoviruses is to provide cells with the E4-orf6 gene stably integrated into the genome of the complementing/packaging cell line. Such cells have been described in the art (e.g. WO 96/22378). A
- 25 disadvantage of that system is the fact that new stable cell lines have to be generated, and numerous selection rounds have to be performed before stable and proper cells have been generated. This process is laborious and time-consuming. In general, it can be stated that generation and propagation of
- 30 adenoviruses from serotypes other than serotype 5 (subgroup C), such as subgroup B viruses, has proven to be difficult on Ad5 complementing cells. As has been disclosed by the

applicants in WO 00/70071, recombinant viruses based on subgroup B virus Ad35 can be made by co-transfection of an expression construct containing the Ad35 early region-1 sequences (Ad35-E1). Furthermore, Ad35-based viruses that are
5 deleted only for E1A sequences and not for E1B were shown to replicate efficiently on PER.C6 cells, suggesting that the E1A proteins of Ad5 are able to complement the Ad35-E1A functions (applicant's international application PCT/NL01/00824, not yet published). Moreover, the experiments
10 show that lack of Ad35-E1B results in poor yields on Ad5 complementing cells. WO 00/70071 also discloses cell lines for the production of E1-deleted non-group C adenoviral vectors by further modifying cell lines that are capable of complementing adenovirus serotype 5. WO 00/70071 further
15 suggests that one should establish new cell lines harbouring Ad35-E1 sequences for the complementation of recombinant adenovirus serotype 35 vectors lacking the E1 region (see also applicant's international application PCT/NL01/00824). However, as also discussed above, if one desires to apply a
20 specific serotype for a specific need, one would have to establish a new cell line for every specific serotype, or one would have to modify the available cell lines that can complement adenovirus serotype 5 for complementation of the serotype of interest. It would clearly be advantageous to use
25 the established cell lines that are available in the art, and not to modify these and use them for the production of all other, non-Ad5 serotypes, applying the established and efficient methods known in the art. It is concluded that until the present invention, no flexible and proper
30 'production platform' is available in the art that enables one to produce useful yields of adenovirus serotypes that are different from the serotypes of subgroup C.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a schematic representation of plasmid
p Δ MT.Orf6.Hygro (ECACC deposit no. P02041226). For the sake
5 of clarity, the capital D stands for delta (Δ).

Figure 2 is a schematic representation of plasmid
pAd35. Δ MT.Orf6. For the sake of clarity, the capital D
stands for delta (Δ).

10 Figure 3 is a schematic representation of pUC.35-5E4.

Figure 4 is a representation of the cloning steps leading to
pUC.35-5E4.

15 Figure 5 is a schematic representation of pBr.Ad35.PRn.

Figure 6 is a schematic representation of pBr.Ad35.PR5E4
(ECACC deposit no. P02041229).

20 Figure 7 is a schematic representation of pWE.Ad35.pIX-
rITR.5E4.

Figure 8 is a schematic representation of pCRscriptAmp.NFI-
25 NcoIR.

Figure 9 is a schematic representation of pCRscriptAmp.NcoIF-
NR2.

30 Figure 10 is a schematic representation of pCR.NF1-NR2.

Figure 11 shows the alignment between the amino acid sequence of E4-orf6 of Adenovirus serotype 5 (SEQ ID NO:21; upper sequence) with the amino acid sequence of the E4-orf6 protein from Adenovirus serotype 5 cloned into the Ad35 backbone (SEQ ID NO:21; middle sequence; NB. identical to E4-orf6 of Ad5, upper sequence) as obtained by determination of the nucleotide order, and the amino acid sequence of the E4-orf6 protein of Adenovirus serotype 35 (SEQ ID NO:22; lower sequence), showing that the entire fragment encoding the E4-orf6 protein in the Adenovirus serotype 35 backbone has been replaced by the fragment encoding the E4-orf6 protein of Adenovirus serotype 5.

Figure 12 shows the alignment between the amino acid sequence of the E4-orf6/7 protein of Adenovirus serotype 5 (SEQ ID NO:23; upper sequence) with the amino acid sequence of the E4-orf6/7 fusion protein encoded partly by the Adenovirus serotype 5 E4-orf6/7 fragment replacing the corresponding part of the adenovirus serotype 35 E4-orf6/7 fragment in the Adenovirus serotype 35 backbone (SEQ ID NO:24; middle sequence) and the amino acid sequence of the E4-orf6/7 protein of Adenovirus serotype 35 (SEQ ID NO:25; lower sequence), showing that the orf6/7 sequence is partly chimeric, with the fusion approximately at the lysine (K) residue at position 138. For the sake of clarity, the notation orf6+7 should be read as the open reading frame orf6/7, which is a separate open reading frame within the E4 region of adenoviruses besides orf6 and orf7, being a notation well known to persons skilled in the art.

Figure 13 is a schematic representation of pBr.Ad35.PR.5Orf6 (ECACC deposit no. P02041227).

Figure 14 is a schematic representation of pWE.Ad35.pIX-rITR.5Orf6.

- 5 Figure 15 is a schematic representation of pBr.Ad35.PRn Δ E3. For the sake of clarity, the capital D stands for delta (Δ).

Figure 16 is a schematic representation of pBr.Ad35. Δ E3.PR5E4. For the sake of clarity, the capital D
10 stands for delta (Δ).

Figure 17 is a schematic representation of pBr.Ad35. Δ E3.PR5Orf6. For the sake of clarity, the capital D stands for delta (Δ).

15

Figure 18 shows the system for producing recombinant adenoviral particles in cells such as PER.C6 through a double homologous recombination event.

- 20 Figure 19 is a schematic representation of pWE.Ad35.pIX-EcoRV.

SUMMARY OF THE INVENTION

The present invention provides recombinant adenovirus vectors comprising structural and non-structural elements of an adenovirus of a first serotype, wherein said vector
5 further comprises a sequence encoding an E4-orf6 protein, wherein said sequence is selected from the group consisting of: a) an E4-orf6 encoding sequence derived from an adenovirus of a second serotype different from said first
10 serotype; b) an E4-orf6 encoding sequence derived from an adenovirus of said first serotype by way of a deletion, mutation, addition and/or substitution in one or more codons; and c) an E4-orf6 encoding sequence comprising a fusion
15 between a part of an E4-orf6 encoding sequence derived from a second serotype different from said first serotype and a part of an E4-orf6 encoding sequence derived from a third serotype, wherein said third serotype may be identical to-, or different from said first serotype.

The invention further provides methods for the production
20 of such recombinant adenovirus vectors comprising structural and non-structural elements of an adenovirus of a first serotype, said method comprising the steps of: a) providing a complementing cell harbouring an E1B-55K encoding sequence, derived from an adenovirus of a second serotype in
25 expressible form, with the necessary elements of an adenovirus such as to allow assembly of said recombinant adenovirus vector by said complementing cell, wherein said elements comprise at least some structural and non-structural elements from an adenovirus of said first serotype different
30 from said second serotype and a sequence encoding a functional E4-orf6 protein, or a functional part, derivative and/or analogue thereof, which is compatible with said

expressible E1B-55K protein in said complementing cell; b) culturing said complementing cell in a medium under conditions allowing for production and assembly of the adenovirus vector to take place; and c) harvesting the
5 recombinant adenovirus vector so produced from the medium and/or the complementing cell, wherein the sequence encoding the compatible E4-orf6 protein is present in the recombinant adenovirus vector so produced.

The invention further relates to pharmaceutical
10 compositions comprising adenoviral vectors according to the invention and the treatment of individuals using the adenoviral vectors provided by the present invention. The invention also relates to a kit of parts comprising cell
lines and adenoviral vectors provided by the invention for
15 executing the methods provided by the invention.

DETAILED DESCRIPTION

The present invention discloses methods and means that solve certain difficulties related to diminished
5 complementation of non-group C adenoviral vectors in Ad5 packaging/complementing cells. Although in the Ad5 complementing cell lines functional Ad5 E1B-55K expression is present, it was found that only very low titers of adenoviral vectors could be produced when the adenoviral backbone was of
10 a non-group C adenoviral origin; this finding implies a serotype-specificity in the interaction of E1B-55K with another (viral) protein. It is disclosed here that this serotype-dependency can be circumvented by providing E4-orf6 protein compatible with the E1B-55K protein provided by the
15 complementing cell line. As discussed herein, E1B-55K and E4-orf6 form a complex that is involved in inhibiting transport of cellular mRNA's from the nucleus to the cytoplasm, while the complex is also involved in stimulation of transport of viral mRNA's from the nucleus to the cytoplasm. It has been
20 observed by the present inventors that proper complementation of viral vectors in packaging cells requires the presence of E1B-55K and E4-orf6 gene products that are compatible. Packaging cells are also referred to as complementing cells, if the cells comprise certain sequences encoding proteins
25 that complement functions not provided by the vector that should be packaged. 'Compatible' as used herein therefore means that a complex between the available E1B-55K gene product is able to form a functional complex with the available E4-orf6 gene product in a sense that this protein
30 complex supports viral replication, propagation and/or packaging to a level that is comparable to the wild-type situation or that is comparable to the situation found when a

recombinant adenovirus serotype 5 vector is produced on a Ad5 complementing cell line such as 293 or PER.C6. Vector replication in packaging cells is efficient if, during production period in which the virus is formed, the cell

5 comprises at least E1B-55K protein and E4-orf6 protein that are compatible. Preferably, the E1B-55K and E4-orf6 sequences are from adenoviruses within the same adenovirus subgroup (such as A, B, C, D, E or F). More preferably, the E1B-55K and E4-orf6 sequences are from the same serotype. Since

10 established cell lines are available in the art that are capable of supporting the growth of adenoviruses of subgroup C, such as serotype 5, it is even more preferred that the E1B-55K and E4-orf6 genes are derived from adenovirus serotype 5. As will be understood by the skilled person

15 compatibility may be determined in complementation tests or assays as such in the realm of those skilled in the art of adenoviral vector production. The person skilled in the art will also understand that the present invention can also be used for the production of any adenovirus serotype on any

20 complementing cell line as long as the E1B-55K and E4-orf6 proteins are compatible.

It has further been observed that the E4-orf6 gene product, 'matching' with the E1B in the complementing cell line, can be provided by the adenoviral vector, by replacing

25 the E4-orf6 in the adenoviral vector of choice with an E4-orf6 encoding sequence that is compatible with the E1B gene present within the packaging cell line. This modification was surprisingly found not to have a severe effect on the stability, replication, packaging, assembly and production of

30 the vector.

It is a specific aspect of the invention that one is now able to efficiently produce adenovirus serotypes different

than those from subgroup C on cell lines normally applied for the production of adenovirus serotype 5 or other serotype from subgroup C, such as serotype 1, 2 and 6. The present invention provides methods for the production of non-group C
5 adenoviruses without the necessity of separately providing the complementing (packaging) cell with E4-orf6 because the E4-orf6 sequence, that is compatible with the complementing E1B-55K sequence, is incorporated in the adenoviral backbone.

The present invention provides a recombinant adenovirus
10 vector comprising structural and non-structural elements of an adenovirus of a first serotype, wherein said vector further comprises a sequence encoding a functional E4-orf6 protein, or a functional part, derivative and/or analogue thereof, wherein said sequence is selected from the group
15 consisting of: a) an E4-orf6 encoding sequence derived from an adenovirus of a second serotype different from said first serotype; b) an E4-orf6 encoding sequence derived from an adenovirus of said first serotype comprising a deletion, mutation, addition and/or substitution in one or more codons;
20 and c) an E4-orf6 encoding sequence comprising a fusion between a part of an E4-orf6 encoding sequence derived from a second serotype different from said first serotype and a part of an E4-orf6 encoding sequence derived from a third serotype, wherein said third serotype may be identical to-,
25 or different from said first serotype. In one embodiment, the present invention provides a recombinant adenovirus vector according to the invention, wherein said first serotype and said second serotype are from different adenovirus subgroups. In a preferred embodiment, a recombinant adenovirus vector
30 according to the invention is provided, wherein said first serotype is from a subgroup other than subgroup C and wherein said E4-orf6 encoding sequence is derived from an adenovirus

serotype of subgroup C. More preferred is a recombinant adenovirus according to the invention, wherein said first serotype is from subgroup B and said second serotype is from subgroup C. Even more preferably, said E4-orf6 encoding
5 sequence is derived from adenovirus serotype 5.

It has been recognized by those skilled in the art that different levels of neutralizing antibodies circulate in humans that are directed against different serotypes. It has been found that certain adenoviral serotypes encountered high
10 titers of such neutralizing antibodies and that many individuals in different populations carried neutralizing antibodies against such serotypes. It was also found that certain serotypes were only neutralized in a minority of the samples (WO 00/70071). Apparently, certain serotypes from
15 subgroup B were only neutralized in a small group of samples. Therefore, in a preferred embodiment of the present invention, recombinant adenovirus vectors according to the invention are provided, wherein said first serotype is selected from the group consisting of adenovirus serotypes
20 11, 14, 16, 21, 34, 35 and 50. Highly preferred are recombinant adenoviral vectors, wherein said first serotype is serotype 11 or 35, while these encountered neutralizing antibodies only in a very small percentage of the tested samples.

25 The vectors of the present invention can be used in different settings such as gene therapy, functional genomics, tumour vaccination and/or anti-viral vaccination. For this, it is necessary that the adenoviral vector functions as a gene delivery vehicle, wherein a non-native gene is
30 incorporated into the adenoviral genome. The adenoviral particle can subsequently be targeted specifically to target cells of interest; the adenovirus binds to that specific cell

either through capsid-receptor binding or through other means, and delivers the transgene. Targeting of adenoviruses can be performed in many different ways. Persons skilled in the art of adenoviral vector targeting will be aware of all the different possibilities that are applied to deliver the adenoviral vectors to the cells of interest. Such possibilities include but are not limited to capsid alterations (fiber, hexon and/or penton modifications, such as deletions, swaps between fibers of different serotypes, and additions of peptides and/or other binding moieties), wherein chimeric fibers are produced that recognize a receptor present on the cell of interest, or wherein the binding of the penton-base is utilized. Other possibilities are linking targeting moieties to the capsid proteins, wherein for instance binding peptides, known and strong binding proteins, or antibodies or parts thereof are linked to the capsid proteins to achieve specific targeting. Such vectors can all be produced using the methods and means provided by the present invention. Therefore, the present invention also discloses recombinant adenovirus vectors according to the invention, further comprising a sequence encoding a non-adenoviral protein, polypeptide or peptide. Such sequences can be present on different locations within the adenoviral backbone, but preferably it is located in the E1 region, which is lacking in the recombinant adenoviral vectors of the invention. The E1 region is complemented by (the complementation) elements present in the complementing cells. The direction of the promoter, transgene and other regulatory sequences can be directed towards the left-, as well as to the right inverted terminal repeat.

The present invention can also be used for the production of viral vectors based on adenovirus and/or on

other viruses such as the Adeno-Associated Virus (AAV), wherein the combination, such as an Ad-AAV chimeric virus, can integrate into the host cell genome. Several methods are known in the art for generating integrating adenoviruses.

- 5 Generally, the invention is also useful for the production of adenovirus forms that (specifically, or non-specifically) can integrate.

As mentioned, several non-adenoviral transgenes can be cloned into the recombinant adenoviral vectors of the present
10 invention. These do not only include regulatory nucleic acid sequences such as enhancers, promoters (e.g. strong non-adenoviral promoters such as the cytomegalovirus promoter, the SV40 promoter and the RSV promoter) and polyadenylation signals, but also heterologous genes for therapeutic
15 purposes. Therefore, in one aspect of the invention, recombinant adenovirus vectors according to the invention are provided, wherein said non-adenoviral protein, polypeptide or peptide is selected from the group consisting of: a cell-death inducing polypeptide, an antigenic determinant of a
20 pathogenic organism, a tumor specific antigen, a viral protein, a hormone and a cytokine. Examples of pathogenic organisms are, but are not limited to bacteria, viruses and fungi. Non-limiting examples of non-adenoviral factors, proteins, polypeptides and peptides are transcription factors,
25 intracellular signalling proteins, phosphatases, kinases, apoptosis inhibiting factors, receptor antagonists, soluble forms of membrane-bound receptors, RNA inhibitors, anti-sense RNA's, decoy factors, ribozymes, and more specifically, thymidine kinase, erythropoietin, novel-erythropoiesis
30 stimulating protein (NESP), IL3, cENOS, gamma-interferon and gp100. Non-adenoviral viral proteins can be cloned into the recombinant adenoviral vectors provided by the methods and

means of the present invention for vaccination purposes. Such viral proteins include, but are not limited to, gag, pol, env, nef, etc. for HIV vaccines, E6 and E7 proteins for Human Papilloma Virus vaccines, circumsporozoite proteins from

5 *Plasmodium* protozoa for malaria vaccines, rotavirus components for rotavirus vaccines, ebola proteins for ebola vaccines, the F and G gene products from Respiratory syncytial virus (RSV) for RSV vaccines, HA and NA for influenza vaccines, etc.

10 The recombinant adenoviruses of the present invention comprise structural and non-structural elements. Examples of structural elements are the genes encoding the capsid proteins, such as fiber, hexon and penton proteins, as well as the gene products itself. Examples of non-structural
15 elements are the early genes that are expressed upon infection into a cell and that are downregulated when the infection cycle proceeds. Other examples of non-structural elements are the genes encoding the proteins active during replication, such as pol and pTP. It is to be understood that
20 the recombinant adenoviral vectors may comprise structural and non-structural elements derived from different serotypes. Examples of such vectors are for instance the adenoviral particles carrying chimeric fibers (see applicant's patent application WO 00/03029). Molecular biology techniques have
25 made it possible to construct endless combinations of nucleic acid sequences. It is clear to the person skilled in the art of molecular biology that combining different sequences can be performed using different molecular techniques, such as polymerase chain reaction (PCR) as well as direct subcloning.
30 Many of the sequences used in the present invention as well as sequences and chimeric constructs known in the art are derived from different adenovirus serotypes. 'Derived' as

used herein therefore means that such sequence combinations can be obtained through direct cloning from wild-type sequences obtained from wild-type viruses, while they can for instance also be obtained through PCR by using different
5 pieces of DNA as a template. This means also that such sequences may be in the wild-type form as well as in altered form. Another option for reaching the same result is through combining synthetic DNA. It is to be understood that 'derived' does not exclusively mean a direct cloning of the
10 wild type DNA. A person skilled in the art will also be aware of the possibilities of molecular biology to obtain mutant forms of a certain piece of nucleic acid. These mutations may render a different functionality, but they may also be silent in a way that certain mutations do not alter the
15 functionality of that particular piece of DNA and its encoded protein. Therefore, the terms 'functional part, derivative and/or analogue thereof' are to be understood as equivalents of the nucleic acid they are related to. A person skilled in the art will appreciate the fact that certain deletions,
20 swaps, (point)mutations, additions, etc. may still result in a nucleic acid that has a similar function as the original nucleic acid. It is therefore to be understood that such alterations that do not significantly alter the functionality of the proteins such as the E4-orf6 and E1B-55K gene product
25 are within the scope of the present invention.

Some alterations in the nucleic acid, such as a deletion, a mutation, addition and/or substitution in one or more codons may also significantly change the structure and/or functionality of the encoded gene product. The present
30 invention therefore also relates to E4-orf6 encoded sequences that are derived from the same adenovirus serotype as the backbone harbouring the genes for instance the structural and

non-structural elements, but wherein the E4-orf6 encoding sequence has been mutated such that it has become compatible with the E1 proteins (such as the E1B-55K gene product) present in the complementing cell in which the adenoviral vector is to be produced. The codon may be altered completely to change the encoded amino acid, but it may also be mutated partly to change the encoded amino acid. Deletions of nucleic acids may result in loss of one or more encoded amino acids; while it may also result in frame-shifts. The present invention also relates to E4-orf6 sequences present in the adenoviral nucleic acid that comprise different parts derived from different serotypes, wherein the domains that render the protein functional in compatibility may be used from one serotype, while the remainder of the E4-orf6 sequence or a part thereof is derived from another (un)related serotype (for instance from the same subgroup, from different subgroups or from different species, or combinations thereof). It is therefore also within the scope of the present invention to apply E4-orf6 fusion proteins that are compatible. Such fusion protein may be the product of several pieces of nucleic acid.

A person skilled in the art will be aware of the fact that besides all human adenoviruses numerous non-human adenoviruses have been identified in the art. Obviously, also non-human adenoviruses can be applied to reach the same results as disclosed by the present invention. It will be clear to the skilled person that compatibility between E1B-55K and E4-orf6 may not be limited to human adenoviruses but that also elements from adenoviruses specific for different species can be compatible. Thus, it is another aspect of the invention that non-human adenoviruses can be produced to high titers on known packaging cell lines available in the

art as long as the E1B-55K and E4-orf6 gene products are compatible. Non-limiting examples of non-human adenoviruses that can be produced using the methods and means of the present invention are canine-, bovine-, ovine-, frog-,
5 porcine, equine-, monkey- and avian adenoviruses. Serotypes as used herein therefore goes beyond species-restricted serotypes. If for instance a monkey adenovirus E4-orf6 gene product is compatible with the E1B-55K provided by the packaging cell, then this combination is within the scope of
10 the present invention. Also, when fusions are applied between different serotypes, or between E4-orf6 sequences derived from for instance a human and an avian adenovirus that is compatible with the E1B gene of the packaging cell, then that particular combination is also within the scope of the
15 present invention.

The present invention provides a method for producing a recombinant adenovirus vector comprising structural and non-structural elements of an adenovirus of a first serotype, said method comprising the steps of: a) providing a
20 complementing cell harbouring an E1B-55K encoding sequence, or a functional part, derivative and/or analogue thereof, derived from an adenovirus of a second serotype in expressible form, with the necessary elements of an adenovirus such as to allow assembly of said recombinant
25 adenovirus vector by said complementing cell, wherein said elements comprise at least some structural and non-structural elements from an adenovirus of said first serotype different from said second serotype and a sequence encoding a functional E4-orf6 protein, or a functional part, derivative
30 and/or analogue thereof, which is compatible with said expressible E1B-55K protein in said complementing cell; b) culturing said complementing cell in a medium under

conditions allowing for production and assembly of the adenovirus vector to take place; and c) harvesting the recombinant adenovirus vector so produced from the medium and/or the complementing cell, wherein the sequence encoding the compatible E4-orf6 protein is present in the recombinant adenovirus vector so produced.

In one aspect of the invention, a method according to the invention is provided, wherein said E4-orf6 encoding sequence is selected from the group consisting of: i) an E4-orf6 encoding sequence derived from an adenovirus of said second serotype; ii) an E4-orf6 encoding sequence derived from an adenovirus of a third serotype different from said first and second serotype; iii) an E4-orf6 encoding sequence derived from an adenovirus of said first serotype comprising a deletion, mutation, addition and/or substitution in one or more codons; and iv) an E4-orf6 encoding sequence comprising a fusion between a part of an E4-orf6 encoding sequence derived from a third serotype and a part of an E4-orf6 encoding sequence derived from an adenovirus of said second serotype, wherein said third serotype may be identical to-, or different from said first serotype. In a preferred embodiment, said first and said second serotypes are from different subgroups. In a more preferred embodiment, said second serotype is an adenovirus serotype of subgroup C. In an even more preferred embodiment, said second serotype is adenovirus serotype 5. In other particular aspect of the invention, said first serotype is an adenovirus serotype of subgroup B. Preferably, said first serotype is selected from the group consisting of adenovirus serotypes 11, 14, 16, 21, 34, 35 and 50.

There are several packaging cells known in the art that are used for complementing recombinant adenoviral vectors and

to produce, assemble and package the adenoviral particles. Non-limiting examples of such cell lines are HEK-293, 911 and PER.C6™ cells. It is preferred to use cell lines that have already proven to deliver high titers of adenoviral stocks.

- 5 Such cell lines express E1 proteins in a stable manner, it is therefore a preferred aspect of the invention to use cell lines and methods, wherein said E1B-55K encoding sequence is integrated into the genome of said complementing cell. More preferred are complementing cells that are derived from a
- 10 primary, diploid human cell, or a progenitor cell thereof. Even more preferred, said complementing cell is derived from a primary human retinoblast cell, a primary human embryonic kidney cell, a primary human neuronal cell or a primary human amniocyte. Highly preferred is the use of a complementing
- 15 cell in the methods provided by the present invention, wherein said complementing cell is a PER.C6 cell or a derivative thereof. PER.C6 cells are well known in the art for not giving rise to replication competent adenovirus when adenoviral DNA is used that has no overlap with the nucleic
- 20 acid provided by the cells. Many of the adenoviral vectors used in the art lack the E1 region, therefore in one aspect of the invention, said complementing cell comprises, integrated into its genome, a nucleic acid encoding at least one adenovirus E1A protein. Preferably, said nucleic acid
- 25 encoding at least one adenovirus E1A protein is derived from an adenovirus serotype of a subgroup different than subgroup B. More preferably, said nucleic acid encoding at least one adenovirus E1A protein is derived from an adenovirus serotype of subgroup C. Highly preferred are embodiments wherein said
- 30 nucleic acid encoding at least one adenovirus E1A protein is derived from an adenovirus serotype 5. In another embodiment of the invention, the invention provides a method, wherein

said E4-orf6 encoding sequence and said E1B-55K encoding sequence are derived from different adenovirus serotypes and wherein said different adenovirus serotypes are members of the same adenovirus subgroup. Preferably, said E4-orf6
5 encoding sequence and said E1B-55K encoding sequence are derived from different adenovirus serotypes and wherein said different adenovirus serotypes are both members of subgroup C. More preferably, said E4-orf6 encoding sequence and said E1B-55K encoding sequence are derived from the same
10 adenovirus serotype. Highly preferred are methods, wherein said E4-orf6 encoding sequence and said E1B-55K encoding sequence are derived from adenovirus serotype 5.

The present invention also relates to a pharmaceutical composition comprising a recombinant adenoviral vector
15 according to the invention or obtainable by a method provided by the invention. The pharmaceutical composition further comprises an acceptable pharmaceutical carrier, generally applied by persons skilled in the art of preparation of pharmaceuticals. Furthermore, the present invention relates
20 to a method of treating a human body comprising administering to a human body a recombinant adenoviral vector according to the invention, or a pharmaceutical composition provided by the invention. The invention also relates to methods in which adenoviral vectors can be produced using the proper
25 complementing/packaging cells and the adenoviral vector of interest. For an efficient production process it is useful to apply the correct cells with the proper adenoviral vector. Therefore, the invention also relates to a kit of parts comprising: a) a complementing cell for producing a
30 recombinant adenovirus vector comprising structural and non-structural elements of an adenovirus of a first serotype, said cell harbouring an E1B-55K encoding sequence, or a

functional part, derivative and/or analogue thereof, derived from an adenovirus of a second serotype in expressible form; and b) on one or more replicable nucleic acid vectors all necessary adenoviral elements such as to allow assembly of said recombinant adenovirus vector by said complementing cell, wherein said elements comprise at least some structural and non-structural elements from an adenovirus of said first serotype different from said second serotype and a sequence encoding a functional E4-orf6 protein, or a functional part, derivative and/or analogue thereof, which is compatible with said expressible E1B-55K protein in said complementing cell. Preferably, a kit of parts is used, wherein said E4-orf6 encoding sequence is selected from the group consisting of:

a) an E4-orf6 encoding sequence derived from an adenovirus of said second serotype; b) an E4-orf6 encoding sequence derived from an adenovirus of a third serotype different from said first and second serotype; c) an E4-orf6 encoding sequence derived from an adenovirus of said first serotype comprising a deletion, mutation, addition and/or substitution of one or more codons; and d) an E4-orf6 encoding sequence comprising a fusion between a part of an E4-orf6 encoding sequence derived from a third serotype and a part of an E4-orf6 encoding sequence derived from an adenovirus of said second serotype, wherein said third serotype may be identical to-, or different from said first serotype.

The invention is particularly useful for the replication of E1 deleted chimeric adenoviruses that are derived almost entirely from a serotype other than adenovirus 5. Such vectors need only to be provided with a nucleic acid encoding adenovirus 5 E4orf6 or a functional part, derivative and/or analogue thereof. Once provided therewith the vector can be efficiently replicated on normal adenovirus 5 E1-

complementing packaging cell lines. Stability of the vectors is improved, and vectors may be complemented for deletions in both E1A and E1B. By providing such vectors with a nucleic acid encoding adenovirus E4crf6, it is possible to enable
5 efficient plaque purification and good yields in the absence of an additional wild type contamination problem, when grown on 293 or 911 cells. In PER.C6, of course, wild type adenovirus contamination can also be prevented in other ways.

An additional advantage of a recombinant vector of the
10 invention is that there is no need to generate special cell lines adenovirus E4-orf6 from a nucleic acid integrated into the genome. Although such cell lines exist, they are not easily maintained in good order. This is at least in part due to the fact that with more and more foreign genes inserted
15 into the genome of cell line it is difficult to maintain stability of all foreign sequences (or the expression thereof). In the present invention it was found that at least some of the problems associated with low yields of non-adenovirus serotype 5 based vectors and stability of
20 adenovirus serotype vectors from subgroup B, such as adenovirus serotype 7, 11 and 35 on adenovirus serotype 5 packaging cell lines can be overcome with a recombinant adenovirus vector of the invention.

EXAMPLES

Example 1. Generation of E1-deleted Ad35 viruses expressing Ad5 E4-Orf6 on an Ad5 complementing cell line.

5 The sequencing of the Adenovirus serotype 35 genome as well as the construction of a plasmid-based vector system and generation of recombinant Ad35-based viruses have been described in detail in WO 00/70071.

10 The cloning of the Ad5-E4-orf6 coding sequence into pAdApt35IP1 (ECACC deposit no. P02041228, for cloning details of this plasmid see WO 00/70071) was performed as follows. The plasmid was digested with NheI and AvrII and dephosphorylated with Calf Intestine Phosphatase (New England Biolabs). Digested DNA was isolated from gel using the
15 GeneClean kit. Plasmid pAMT.Orf6.Hygro (Figure 1, ECACC deposit no. P02041226) was digested with NheI and subsequently partially digested with XbaI. After separation of the resulting bands on gel, the 1350 bp fragment
20 corresponding to the Δ MT promoter linked to the E4-orf6 sequence was purified from gel. Next, both isolated fragments were ligated and transformed into electro-competent DH10B cells (Invitrogen/LifeTechnologies) after which a colony with the insert in the correct orientation with respect to the SV40 poly(A) signal was selected for large scale DNA
25 preparation. This resulted in construct pAd35. Δ MT.Orf6 (Figure 2), which contains the Ad5 E4-orf6 coding sequence functionally linked to a mutated metallothionein promoter (Δ MT). The Δ MT promoter has been described by Hagmeyer et al. (1996). The Ad5 E4-orf6 sequence corresponds to nucleotide
30 33193 to nucleotide 34077 in the Ad5 sequence (Genbank accession number M73260). To test whether the expression of Ad5 E4-orf6 proteins would make production of fully E1-

deleted Ad35 vectors possible on Ad5 complementing cells, pAd35. Δ MT.Orf6 was co-transfected with the Ad35 backbone construct pWE.Ad35.pIX-rITR onto PER.C6 cells. Hereto, pAd35. Δ MT.Orf6 was digested with PI-Psp-1 and pWE.Ad35.pIX-rITR was digested with NotI to liberate the adenoviral inserts from the backbone. 2 μ g of digested pAd35. Δ MT.Orf6 and 6 μ g of digested pWE.Ad35.pIX-rITR were transfected using LipofectAmine. The transfection mixture was added to PER.C6 cells that were seeded the day before at a density of 3.5×10^6 cells per T25 flask. The next day the medium was changed for PER.C6 culture medium (DMEM with 10% FBS and 10 mM $MgCl_2$) and cells were further incubated at 37°C/10% CO_2 . Control transfections were performed with pAdApt35.Luc co-transfected with pWE.Ad35.pIX-rITR, and pWE.Ad35.pIX-rITR alone. Two days after transfection, cells were passed from T25 to T80 flasks and incubated as described. Again three days later the culture transfected with pAd35. Δ MT.Orf6 together with the Ad35 backbone showed cytopathogenic effect (CPE) indicative of virus replication, and was harvested (including cells and medium) after a further incubation of 2 days. The cell suspension was subjected to 2 rounds of freeze/thaw cycles and the resulting material (crude lysate) was kept at -20°C until further use. The other flasks did not show CPE and were passed 1:3 in T80 flasks 6 days after transfer to T80. Again 5 days later the pAdApt35.Luc + pWE.Ad35.pIX-rITR transfected flask showed a few CPE-like events but this did not progress further. 0.2 and 0.5 ml of the crude lysate resulting from the pAd35. Δ MT.Orf6 transfection was used to re-infect PER.C6 cells at approximately 85% confluency in T80 flasks. This resulted in full CPE after one day of incubation indicating that infectious virus was present in the crude lysates. These

cultures were also harvested by two freeze/thaw cycles.

Additional control transfections with construct

pAd35. Δ MT.Orf6 alone onto PER.C6 were performed to confirm

that orf6 expression by itself did not result in cell

- 5 toxicity and CPE-like cell death. In conclusion, only the transfections with pAd35. Δ MT.Orf6 together with pWE.Ad35.pIX-rITR did result in CPE and virus replication.

- PCR analysis was performed to confirm the presence of Ad35-based viral genomes with Ad5-E4-orf6 replacing the
- 10 former E1 region. Hereto, viral DNA was isolated from the crude lysate samples as follows. 275 μ l of crude lysate material was incubated with 10 μ l DNaseI (10 mg/ml) at 37°C for 30 min. Subsequently, 6.0 μ l 0.5 M EDTA (pH 8.0), 7.5 μ l 20% SDS and 1.5 μ l 20 mg/ml Proteinase K was added and mixed
- 15 by vortexing. The mixture was then incubated at 50°C for 1 h. Finally, the viral DNA was isolated using the GeneClean Spin Kit (Bio 101, Inc.). 2 μ l of the isolated DNA was then PCR amplified using primers 35psi-For and 35R4 (Table 1). The program was set at 94°C for 2 min followed by 30 cycles of
- 20 94°C for 30 sec, 58°C for 30 sec and 72°C for 5 min, and ended by an incubation at 72°C for 10 min. The primers are specific for Ad35 sequences and generate a fragment of 2.9 kb ranging from the packaging sequence to nt 4669 (numbering as in wt Ad35 sequence) thus including the Ad5 orf6 transgene
- 25 cassette. Electrophoresis of the obtained PCR fragments showed that the fragments had the expected length matching with the control PCR fragments generated on the adapter plasmid pAd35. Δ MT.Orf6. Thus, fully E1-deleted Ad35-based vectors can be made on Ad5 complementing cells if the virus
- 30 also expresses Ad5-E4orf6.

Example 2. Construction of pWE.Ad35.pIX-rITR5E4

A first PCR fragment was amplified using primers DF35-1 and 35FR (Table 1). Amplification was done with pWE.Ad35.pIX-rITR (see WO 00/70071) as template DNA using Pwo DNA polymerase (Roche) with additional DMSO (Sigma, final concentration 3%). The program was as follows: 94°C for 2 min followed by 30 cycles of (94°C for 30 sec, 52°C for 30 sec, 72°C for 3 min) and a final step of 72°C for 8 min to ensure complete fragments. Amplification resulted in a 1.6 kb fragment corresponding to nt 30224 to 31805 of the Ad35 sequence. A BamHI site was introduced at the 3' end. The amplified DNA was purified from gel using the GeneClean kit and ligated to the pCRScript/Amp cloning vector kit (Stratagene). Following transformation into electro-competent DH10B cells white colonies were selected for further analysis. This resulted in construct pCR-fiber35. Due to the blunt cloning the PCR fragment could be inserted in 2 orientations. A clone that had the insert with the BamHI site in the polylinker of the pCRScript/Amp vector at the 5' end was selected. Digestion with BamHI thus results in a 1.6 kb fragment. Sequencing confirmed correct amplification of the PCR fragment. A second PCR fragment was amplified using primers: 5E4F and 5E4R (Table 1). Amplification was done with pWE.Ad5.AflIII-rITRsp, which is a cosmid vector containing an extra PacI site in pWE.Ad5.AflIII-rITR (ECACC deposit no. P97082116 described in applicant's international patent application PCT/NL01/00824). pWE.Ad5.AflIII-rITRsp served as a template using Pwo DNA polymerase as described above, although pWE.Ad5.AflIII-rITR could also be used for the same purpose. After purification from gel, the DNA was digested with SstI and BamHI (both sites introduced during the PCR) and the 3 kb fragment was purified from agarose gel using the

GeneClean kit. The Ad5 E4 region that is amplified corresponds to bp 32794 to bp 35828 of the Ad5 sequence. A third PCR fragment was generated on pWE.Ad35.pIX-rITR using primers: 355ITR and 353ITR (Table 1). PCR amplification was performed as described above. The resulting 160 bp fragment is flanked by an SstI site (5' end) and an EcoRI site (3' end). After purification from gel as above, the DNA was digested with SstI and EcoRI. The 160 bp fragment corresponding to the right ITR of Ad35 was then separated from digested ends on a low melting point agarose gel and collected in gel. Next, pUC119 was digested with BamHI and EcoRI and the 3.1 kb fragment was purified from gel using the GeneClean kit. The above treated second and third PCR fragments were then ligated with BamHI/EcoRI digested pUC119 resulting in pUC.Ad5E4-35ITR. The cloned PCR derived inserts were sequenced to verify correct amplification. Next, the 1.6 kb insert in pCR-fiber35 was excised with BamHI and the fragment was purified from gel as above. pUC.Ad5E4-35ITR was also digested with BamHI and the linear fragment was purified from gel. Ligation of both fragments and selection of the clones that had the correct orientation relative to each other resulted in pUC.35-5E4 (Figure 3). The steps leading to the construction of pUC.35-5E4 are schematically represented in Figure 4. The adenovirus insert in pUC.35-5E4 was sub-cloned into pBr.Ad35.PRn (Figure 5; see WO 00/70071), a construct with Ad35 3' sequences. Hereto, construct pUC.35-5E4 is digested with MluI and NotI and the 4.7 kb fragment is purified from gel using the GeneClean kit. This fragment is then ligated with the vector fragment resulting from MluI and NotI digestion of construct pBr.Ad35.PRn. This 16.3 kb fragment was purified from gel using agarase enzyme (Roche). Ligations were then transformed into competent DH10B cells.

The resulting construct was named pBr.Ad35.PR5E4 (Figure 6, ECACC deposit no. P02041229). The last step entails cloning of the modified 3' end of the Ad35 sequence into the viral cosmid clone pWE.Ad35.pIX-rITR. Hereto, two fragments are
5 combined in a lambda phage packaging reaction (Stratagene) according to manufacturer's instructions. The first is the 16.8 kb modified Ad35 insert from pBr.Ad35.PR5E4 obtained by digestion with PacI and SmaI and the second is a 22.8 kb fragment obtained by digestion of pWE.Ad35.pIX-rITR with PacI
10 and SmaI. The correct combination of the two fragments yields pWE.Ad35.pIX-rITR.5E4 (Figure 7). Thus, in this construct the E4 region in the Ad35 backbone is replaced with the corresponding region derived from Ad5.

15 **Example 3. Construction of pWE.Ad35.pIX-rITR5Orf6.**

To obtain an adenoviral backbone construct that contains the Ad35 sequences from the pIX gene (nt 3401 in the Ad35 sequence) to the end of the right ITR but with the sequences for E4-orf6 and -orf6/7 exchanged for the corresponding
20 sequences of Ad5, Ad35 and Ad5 sequences were PCR amplified and combined as described below. PCR fragments were generated with Pwo DNA polymerase with addition of DMSO up to 3%. The first PCR was done with pBr.Ad35.PRn (Figure 5; see WO 00/70071) as template and the primers E4-F1 and E4-R2 (Table
25 1). The program was set as follows: 94°C for 2 min, 5 cycles of (94°C for 30 sec, 50°C for 30 sec and 72°C for 1 min) followed by 30 cycles of (94°C for 30 sec, 60°C for 30 sec and 72°C for 1 min) and ended with a final step at 68°C for 8 min. The resulting 1.8 kb fragment was purified using the
30 GeneClean kit. The second PCR was done with pWE.Ad5.AflIII-rITRsp, which is a cosmid vector containing a PacI site in pWE.Ad5.AflIII-rITR (ECACC deposit no. P97082116, described in

applicant's international patent application PCT/NL01/00824, not yet published), as template and the primers E4-F3 and E4-R4 (Table 1). The program was set as follows: 94°C for 2 min followed by 30 cycles of (94°C for 30 sec, 62°C for 30 sec and 72°C for 1 min) and ended with a final step at 68°C for 8 min. The 1.1 kb fragment was purified as above. The third PCR was done with pBr.Ad35.PRn as template and the primers E4-F5 and E4-R6 (Table 1). The program was set as follows: 94°C for 2 min, 5 cycles of (94°C for 30 sec, 48°C for 30 sec and 72°C for 45 sec) followed by 30 cycles of (94°C for 30 sec, 56°C for 30 sec and 72°C for 45 sec) and ended with a final step at 68°C for 8 min. The 366 bp fragment was purified as above. Samples of the purified fragments were loaded on a gel to estimate the concentration and then the fragments were mixed together to contain 700 ng PCR-1, 650 ng PCR-2 and 430 ng PCR-3 in a total of 30 µl. To this mixture 3 µl EcoPol buffer (New England Biolabs), 3 µl 2 mM dNTP solution and 3 µl milliQ H₂O was added. The resulting mixture was incubated at 94°C for 3 min and then cooled down to 65°C in a PCR machine at a rate of 0.5°C/sec. Following incubation at 65°C for 10 min, the mixture was further cooled down to 20°C at a rate of 0.05°C per sec and incubated for 10 min at 20°C. Then 1 µl (5 units) Klenow enzyme (New England Biolabs) was added followed by an incubation of 60 min at 37°C. 5 µl of this Klenow mixture was used as a template to separately amplify two fragments as follows. Primer set 1: NF-1 and NcoI-R (Table 1) was used in a reaction using Pwo DNA polymerase (Roche) with addition of DMSO to a final concentration of 3% and using the following settings of the PCR machine: 94°C for 2 min followed by 30 cycles of (94°C for 30 sec, 66°C for 30 sec and 72°C for 3 min) followed by a final incubation at 68°C for 8 min. Primer set 2: NcoI-F and NR-2 (Table 1) was used

in a reaction using Pwo DNA polymerase (Roche) with addition of DMSO to a final concentration of 3% and using the following settings of the PCR machine: 94°C for 2 min followed by 30 cycles of (94°C for 30 sec, 62°C for 30 sec and 72°C for 90 sec) followed by a final incubation at 68°C for 8 min. The resulting fragments of 2.7 kb (primer set 1) and 1.1 kb (primer set 2) were purified from gel using the GeneClean kit and each was ligated to the pCRscriptAmp vector (Stratagene) and transformed into DH10B electrocompetent cells. This resulted in construct pCRscriptAmp.NFI-NcoIR (Figure 8) and construct pCRscriptAmp.NcoIF-NR2 (Figure 9). Since the inserts contained blunt ends two orientations were obtained of each cloning. Using KpnI digestions the constructs with the orientation needed for further cloning were selected (see Figures 8 and 9). The inserts were then sequenced to verify correct amplification. Next, part of the insert from pCRscriptAmp-NcoIF-NR2 was excised using BamHI and NcoI and purified from gel as above. pCRscriptAmp-NFI-NcoIR was digested with the same enzymes and the vector containing fragment was also purified from gel. Ligation of these fragments resulted in pCR.NFI-NR2 (Figure 10). pCR.NFI-NR2 contains Ad35 sequences between nt 30162 and 33234 of the Ad35 sequence with E4-orf6 and E4-orf6/7 sequences between nt 31879 and 32974 replaced for Ad5 derived sequences located between 32968 and 34077 from the published Ad5 sequence in Genbank (Accession Number M73260). Thus, as can be seen in the amino acid alignments presented in Figure 11 and 12, the amino acid sequence of the cloned E4-orf6 protein is identical to the E4-orf6 sequence found in Ad5 and the E4-orf6/7 amino acid sequence is for the greater part identical to the E4-orf6/7 sequence present in Ad5. Obviously, different hybrid Ad35-Ad5 E4 constructs can be designed using

the general method outlined above without departing from the invention. This chimeric insert from pCR.NF1-NR2 was then cloned into pWE.Ad35.pIX-rITR: pCR.NF1-NR-2 was digested with MluI and NdeI and the resulting 2.8 kb fragment was purified from gel using the GeneClean kit. Construct pBr.Ad35.PRn was also digested with MluI and NdeI and the 18 kb vector fragment was isolated from gel using agarase enzyme (Roche). Ligation of both fragments resulted in construct pBr.Ad35.PR.5Orf6 (Figure 13, ECACC deposit no. P02041227). The Ad35 sequences between PacI and SmaI containing the chimeric E4 region in this construct are then cloned into construct pWE.Ad35.pIX-rITR using lambda-phage packaging as described above. The resulting pWE.Ad35pIX-rITR.5Orf6 (Figure 14) is then used to generate recombinant Ad35-based viruses by co-transfection on PER.C6 packaging cells with an Ad35 adapter plasmid.

Example 4. Construction of pWE.Ad35.pIX-rITRAE3, pWE.Ad35.pIX-rITRAE3.5E4 and pWE.Ad35.pIX-rITRAE35Orf6.

The Ad35 backbone was further modified by a deletion of E3 sequences. E3 proteins are known to modulate the host immune response to adenovirus infection and are therefore not necessary for *in vitro* propagation of recombinant viruses. Furthermore, the deletion of E3 sequences allows for insertion of larger heterologous sequences in the vectors without compromising the packaging efficiency. Also, for the application of adenoviral vectors as vaccination vehicles, expression of immunomodulatory genes encoded by the E3 region is not preferred. Methods for deleting E3 sequences in the pBr.Ad35.PRn plasmid (Figure 5) are described below.

First a PCR product was generated with primers 35E3for and 35E3rev (Table 1) using Pwo DNA polymerase (Roche)

according to manufacturers instructions and pBr.Ad35.PRn as template DNA. The program was set at 94°C for 2 min and 30 cycles of 94°C for 30 sec, 58°C for 30 sec and 72 °C for 1 min, followed by 68°C for 8 min. The amplified fragment
5 contains Ad35 sequences from nt 26814 to 27647 (see WO 00/70071) and is flanked at the 3' end by an MluI site. The resulting 833 bp fragment was purified using the Qiaquick PCR purification kit (Qiagen) and digested with MluI and StuI. The digested PCR fragment was then purified from an LMP
10 agarose gel using the Qiaquick gel extraction kit (Qiagen). Construct pBr.Ad35.PRn was also digested with MluI and StuI and the 17.3 kb vector containing fragment was isolated from agarose gel using agarase enzym (Roche) using methods known to persons skilled in the art. Both isolated DNAs were
15 ligated and transformed into Max-efficiency DH5α competent bacteria (Invitrogen/LTI) to give pBr.Ad35.PRnΔE3 (Figure 15). The deleted sequences encompass nt 27648 to 30320 of the Ad35 sequence resulting in a 2673 bp deletion. The E3 deletion was then introduced in construct pWE.Ad35.pIX-rITR
20 using lambda-phage packaging extracts (Stratagene). Hereto, both pWE.Ad35.pIX-rITR and pBr.Ad35.PRnΔE3 were digested with PacI and SmaI and the respective 22.8 kb and 14 kb fragments were isolated from low melting point agarose gels using agarase enzym (Roche). After ligation and packaging using
25 STBL-2 cells (Invitrogen/LTI), construct pWE.Ad35.pIX-rITRΔE3 was obtained.

To construct the E3-deleted versions of the E4-modified backbone constructs described above, the E4 modifications
were introduced into the pBr.Ad35.PRnΔE3 construct as
30 follows. Construct pUC.35-5E4 (Figure 3) was digested with MluI and NotI and the 4.7 kb fragment was isolated from gel using the GeneClean II kit. Construct pBr.Ad35.PRnΔE3 was

also digested with MluI and NotI and the 13.6 kb vector fragment was isolated from gel using the GeneClean spin kit. Ligation of these fragments resulted in construct pBr.Ad35. Δ E3.PR5E4 (Figure 16). Construct pCR.NF1-NR2 (Figure 5 10) was digested with MluI, NdeI and BglI (the latter to digest the vector fragment into smaller fragments), and the 2.8 kb fragment was isolated from gel using the GeneClean spin kit. Construct pBr.Ad35.PR Δ E3 was digested with MluI and NdeI, dephosphorylated using CIP enzym (New England 10 Biolabs) and the 15.2 kb vector fragment was also isolated using the GeneClean spin kit. Ligation of these fragments gave construct pBr.Ad35. Δ E3.PR5Orf6 (Figure 17). pBr.Ad35. Δ E3.PR5E4 and pBr.Ad35. Δ E3.PR5Orf6 are then used to swap the 3' PacI-SwaI fragment in pWE.Ad35.pIX-rITR for the 15 corresponding regions from pBr.Ad35. Δ E3.PR5E4 and pBr.Ad35. Δ E3.PR5Orf6 as described intra. This leads to constructs pWE.Ad35.pIX-rITR Δ E3.5E4 and pWE.Ad35.pIX-rITR Δ E3.5Orf6. An alternative method to generate these large cosmids is to use three fragments in the ligation reaction 20 for packaging: a 14.7 kb NotI-PacI fragment from pWE.Ad35.pIX-rITR, the PacI-NotI insert from pBr.Ad35. Δ E3.PR5E4 or pBr.Ad35. Δ E3.PR5Orf6 and the NctI digested pWE15 cosmid vector fragment (Stratagene). This latter fragment can also be isolated from the NotI/PacI 25 digestion of pWE.Ad35.pIX-rITR.

Example 5. Generation of E1- and E1/E3-deleted Ad35-based vectors on PER.C6 cells.

To enable generation of recombinant Ad35 viruses on the 30 complementing cell line PER.C6 using the pBr.Ad35.PRn-based constructs, we first made a new construct containing Ad35 sequences from bp 3401 to bp 24650 of the Ad35 sequence (WO

00/70071) and thus overlaps with both the adapter plasmids and the pBr.Ad35.PRn-based constructs. Transfection of these three plasmids into PER.C6 cells and a double homologous recombination event leads to a complete viral genome and replication of recombinant viruses as outlined in Figure 18. The required plasmid was made by deletion of a large part of the Ad35 sequences in pWE.Ad35.pIX-rITR. Hereto, pWE.Ad35.pIX-rITR was digested with EcoRV and the 29 kb vector containing fragment was purified from a low melting point gel using the Geneclean spin kit. The purified DNA was self-ligated and used to transform DH10B electro-competent bacteria (Invitrogen/LTI) resulting in pWE.Ad35.pIX-EcoRV (Figure 19).

All DNAs used for transfection were digested as indicated in Table 2, heat-inactivated at 65°C for 15 min and used without further treatment in the transfection. PER.C6 cells were seeded the day prior to transfection in T25 flasks at a density of 3×10^6 cells/flask and transfected as indicated in Table 2 using LipofectAmine (Invitrogen/LTI) according to manufacturers instructions, except that the transfection mixture in serum-free DMEM medium (Gibco/BRL) was replaced for PER.C6 culture medium (DMEM, 10% FBS and 10 mM $MgCl_2$) after 5 h. The day after, transfection efficiency was estimated at 50% by fluorescence microscopy. Two days later, cells were trypsinized and reseeded in T80 flasks and further incubated at 37°C/10%CO₂. Six days following transfection all cultures showed full cytopathogenic effect (CPE, indicative for virus propagation) except for the PER.C6 culture transfected with Ad35.AdApt.eGFP + pWE.Ad35.pIX-rITR. One day later, cells and medium in the flasks with CPE were harvested and subjected to two freeze/thaw cycles, clarified from cell debris by centrifugation (10 min at 1500 rpm) and

100 µl of these crude lysates were used to re-infect fresh
PER.C6 cells at 85% confluency in T80 flasks. The
transfection of Ad35.AdApt.eGFP + pWE.Ad35.pIX-rITR that did
not show signs of CPE was harvested by trypsinisation and
5 also treated as above. Two days following infection of fresh
PER.C6 cells all flasks showed full CPE except for the one
that showed no signs of CPE at the time of initial
harvesting. This clearly shows that fully E1-deleted Ad35-
based viruses can be made on PER.C6 cells when the Ad5 E4-
10 orf6 gene product is expressed from the Ad35 backbone.

Table 1. Primer sequences.

	35FR	5'-CGGGATCCACTTTATTTTAGTTGTGTCITC-3' (SEQ ID NO:1)
	35R4	5'-CGGAATTCTTAATTAAGGGAAATGCAAATCTGTGAGG-3' (SEQ ID NO:2)
5	35psi-For	5'-GTGGTATTTATGGCAGGGTG-3' (SEQ ID NO:3)
	DF35-1	5'-CACTCACCACCTCCAATTCC-3' (SEQ ID NO:4)
	5E4F	5'-CGGGATCCGTTTGTGTTATGTTTCAACGTG-3' (SEQ ID NO:5)
	5E4R	5'-GCTGGCGAGCTCGGCGGAGTAACTTGTATGTG-3' (SEQ ID NO:6)
	355ITR	5'-GATCCGGAGCTCACAACGTCATTTTCCACG-3' (SEQ ID NO:7)
10	353ITR	5'-AGGAATTCGCGGCCGCAATTAAATC-3' (SEQ ID NO:8)
	E4-F1	5'-AGAGGAACACATTCCCCC-3' (SEQ ID NO:9)
	E4-R2	5'-GGGGAGAAAGCACTGTGTATTCTGTCAAATGG-3' (SEQ ID NO:10)
	E4-F3	5'-TTTGACAGAATACACAGTCCTTTCTCCCGGCTGG-3' (SEQ ID NO:11)
	E4-R4	5'-ACAAAATACGAGAATGACTACGTCCGGCGTTCC-3' (SEQ ID NO:12)
15	E4-F5	5'-GGACGTAGTCATTCTCGTATTTTGTATAGC-3' (SEQ ID NO:13)
	E4-R6	5'-TCACCAACACACTGGGGG-3' (SEQ ID NO:14)
	NF-1	5'-CCACAACCCCCACTACTCCC-3' (SEQ ID NO:15)
	NR-2	5'-CGTCTCTTCCCTCTCCTCTCC-3' (SEQ ID NO:16)
	NcoI-R	5'-AGGATCATCCGCTGCTGCCC-3' (SEQ ID NO:17)
20	NcoI-F	5'-CATCAGGATAGGGCGGTGG-3' (SEQ ID NO:18)
	35E3for	5'-AATGACTAATGCAGGTGCGC-3' (SEQ ID NO:19)
	35E3rev	5'-CGACGCGTTGTAGTCGTTGAGCTTCTAG-3' (SEQ ID NO:20)

Table 2. List of constructs used to generation E1-deleted Ad35 based viruses on PER.C6 cells as described in the examples. Adapter constructs were digested with PacI, pWE.Ad35.pIX-EcoRV was digested with NotI and EcoRV, E4-
 5 modified pBr-based constructs were digested with PacI and NotI.

No.	Constructs			CPE
1	pAdApt35.eGFP	pWE.Ad35.pIX-EcoRV	pBr.Ad35.PR5E4	Yes
2	pAdApt35.eGFP	pWE.Ad35.pIX-EcoRV	pBr.Ad35.PR5Orf6	Yes
3	pAdApt35.eGFP	pWE.Ad35.pIX-EcoRV	pBr.Ad35.ΔE3PR5E4	Yes
4	pAdApt35.eGFP	pWE.Ad35.pIX-EcoRV	pBr.Ad35.ΔE3.PR5Orf6	Yes
5	pAdApt35.eGFP	pWE.Ad35.pIX-rITRxNotI		No
6	pAdApt5.eGFP	pWE.Ad5.AflII-rITRxPacI		Yes

REFERENCES

- Abrahamsen K, Kong H-L, Mastrangeli A, Brough D, Lizonova A, Crystal R and Falck-Pedersen E. (1997) Construction of an
5 adenovirus type 7a E1A⁻ vector. J Virol 11:8946-8951.
- Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoebe RC and Van der Eb AJ. (1996) Characterization of
10 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 7:215-222.
- Fallaux FJ, Bout A, Van der Velde I, Van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, Van Ormondt H, Van
15 der Eb AJ, Valerio D and Hoebe RC. (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication competent adenoviruses. Hum Gene Ther 9:1909-1917.
- 20 Francki RIB, Fauquet CM, Knudson L and Brown F. (1991) Classification and nomenclature of viruses. Fifth report of the international committee on taxonomy of viruses. Arch Virol Suppl 2:140-144.
- 25 Graham FO, Smiley J, Russell W and Nairn R. (1970) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-72.
- 30 Hagmeyer BM, Duyndam MC, Angel P, De Groot RP, Verlaan M, Elfferich P, Van der Eb AJ and Zantema A. (1996) Oncogene 12:1025-1032.
- Horwitz MS. (2001) Adenovirus immunoregulatory genes and
35 their cellular targets. Virology 279:1-8.
- Leppard KN. (1997) E4 gene function in adenovirus, adenovirus
vector and adeno-associated virus infections. J Gen Virol 78:2131-2138.
- 40 Leppard KN. (1998) Regulated RNA processing and RNA transport during adenovirus infection. Seminars in Virology 8:301-307.
- Pilder S, Moore M, Logan J and Shenk T. (1986) The adenovirus
45 E1B 55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol Cell Biol 6:470-476.

- Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S and White E. (1992) The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 89:7742-7746.
- 5
- Russell WC. (2000) Update on adenoviruses and its vectors. J Gen Virol 81:2573-2604.
- 10
- Shenk T. (1996) Adenoviridae: The viruses and their replication. In Virology, eds. Fields BN, Knipe DM and Howley PM. (Lippincott-Raven, New York) 2:2111-2148.
- 15
- Van der Vliet PC. (1995) Adenovirus DNA replication. In The molecular repertoire of adenoviruses II, eds. Doerfler W and Böhm P. (Springer-Verlag, Berlin). Current Topics in Microbiology and Immunology 199/II:1-30.
- 20
- Yew PR and Berk AJ. (1992) Inhibition of p53 transactivation required for transformation by adenovirus early region 1B protein. Nature 357:82-85.

Claims

1. A recombinant adenovirus vector comprising structural and non-structural elements of an adenovirus of a first serotype, wherein said vector further comprises a sequence encoding a functional E4-orf6 protein, or a functional part, derivative and/or analogue thereof, wherein said sequence is selected from the group consisting of:
1. an E4-orf6 encoding sequence derived from an adenovirus of a second serotype different from said first serotype;
 2. an E4-orf6 encoding sequence derived from an adenovirus of said first serotype comprising a deletion, mutation, addition and/or substitution in one or more codons; and
 3. an E4-orf6 encoding sequence comprising a fusion between a part of an E4-orf6 encoding sequence derived from a second serotype different from said first serotype and a part of an E4-orf6 encoding sequence derived from a third serotype, wherein said third serotype may be identical to-, or different from said first serotype.
2. A recombinant adenovirus vector according to claim 1, wherein said first serotype and said second serotype are from different adenovirus subgroups.
3. A recombinant adenovirus vector according to claim 1, wherein said first serotype is from a subgroup other than subgroup C and wherein said E4-orf6 encoding sequence is

derived from an adenovirus serotype of subgroup C.

4. A recombinant adenovirus according to claim 1, wherein
said first serotype is from subgroup B and said second
5 serotype is from subgroup C.

5. A recombinant adenovirus vector according to claim 1,
wherein said E4-orf6 encoding sequence is derived from
adenovirus serotype 5.

10

6. A recombinant adenovirus vector according to any one of
claims 1 to 5, wherein said first serotype is selected from
the group consisting of adenovirus serotypes 11, 14, 16, 21,
34, 35 and 50.

15

7. A recombinant adenovirus vector according to any one of
claims 1 to 6, further comprising a sequence encoding a non-
adenoviral protein, polypeptide or peptide.

20 8. A recombinant adenovirus vector according to claim 7,
wherein said non-adenoviral protein, polypeptide or peptide
is selected from the group consisting of: a cell-death
inducing polypeptide, an antigenic determinant of a
pathogenic organism, a tumor specific antigen, a viral
25 protein, a hormone and a cytokine.

9. A method for producing a recombinant adenovirus vector
comprising structural and non-structural elements of an
adenovirus of a first serotype, said method comprising the
30 steps of:

- a. providing a complementing cell harbouring an E1B-55K
encoding sequence, or a functional part, derivative

- and/or analogue thereof, derived from an adenovirus of a second serotype in expressible form, with the necessary elements of an adenovirus such as to allow assembly of said recombinant adenovirus vector by said complementing cell, wherein said elements comprise at least some structural and non-structural elements from an adenovirus of said first serotype different from said second serotype and a sequence encoding a functional E4-orf6 protein, or a functional part, derivative and/or analogue thereof, which is compatible with said expressible E1B-55K protein in said complementing cell;
- b. culturing said complementing cell in a medium under conditions allowing for production and assembly of the adenovirus vector to take place; and
- c. harvesting the recombinant adenovirus vector so produced from the medium and/or the complementing cell,

wherein the sequence encoding the compatible E4-orf6 protein is present in the recombinant adenovirus vector so produced.

10. A method according to claim 9, wherein said E4-orf6 encoding sequence is selected from the group consisting of:
1. an E4-orf6 encoding sequence derived from an adenovirus of said second serotype;
 2. an E4-orf6 encoding sequence derived from an adenovirus of a third serotype different from said first and second serotype;
 3. an E4-orf6 encoding sequence derived from an adenovirus of said first serotype comprising a deletion, mutation, addition and/or substitution in one or more codons; and

4. an E4-orf6 encoding sequence comprising a fusion between a part of an E4-orf6 encoding sequence derived from a third serotype and a part of an E4-orf6 encoding sequence derived from an adenovirus of said second serotype, wherein said third serotype may be identical to-, or different from said first serotype.
11. A method according to any one of claims 9 or 10, wherein said first and said second serotype are from different subgroups.
12. A method according to any one of claims 9 to 11, wherein said second serotype is an adenovirus serotype of subgroup C.
13. A method according to claim 12, wherein said second serotype is adenovirus serotype 5.
14. A method according to any one of claims 9 to 13, wherein said first serotype is an adenovirus serotype of subgroup B.
15. A method according to claim 14, wherein said first serotype is selected from the group consisting of adenovirus serotypes 11, 14, 16, 21, 34, 35 and 50.
16. A method according to any one of claims 9 to 15, wherein said E1B-55K encoding sequence is integrated into the genome of said complementing cell.
17. A method according to any one of claims 9 to 16, wherein said complementing cell is derived from a primary, diploid human cell, or a progenitor cell thereof.

18. A method according to any one of claims 9 to 17, wherein
said complementing cell is derived from a primary human
retinoblast cell, a primary human embryonic kidney cell, a
5 primary human neuronal cell or a primary human amniocyte.

19. A method according to any one of claims 9 to 18, wherein
said complementing cell comprises, integrated into its
genome, a nucleic acid encoding at least one adenovirus E1A
10 protein.

20. A method according to claim 19, wherein said nucleic acid
encoding at least one adenovirus E1A protein is derived from
an adenovirus serotype of a subgroup different than subgroup
15 B.

21. A method according to claim 19, wherein said nucleic acid
encoding at least one adenovirus E1A protein is derived from
an adenovirus serotype of subgroup C.
20

22. A method according to claim 20, wherein said nucleic acid
encoding at least one adenovirus E1A protein is derived from
an adenovirus serotype 5.

23. A method according to any one of claims 9 to 22, wherein
said E4-orf6 encoding sequence and said E1B-55K encoding
sequence are derived from different adenovirus serotypes and
wherein said different adenovirus serotypes are members of
the same adenovirus subgroup.
25

24. A method according to any one of claims 9 to 22, wherein
said E4-orf6 encoding sequence and said E1B-55K encoding
30

sequence are derived from different adenovirus serotypes and wherein said different adenovirus serotypes are both members of subgroup C.

5 25. A method according to any one of claims 9 to 22, wherein said E4-orf6 encoding sequence and said E1B-55K encoding sequence are derived from the same adenovirus serotype.

26. A method according to claim 25, wherein said E4-orf6
10 encoding sequence and said E1B-55K encoding sequence are derived from adenovirus serotype 5.

27. A method according to claim 9, wherein said complementing cell is a PER.C6 cell or a derivative thereof.

15

28. A pharmaceutical composition comprising a recombinant adenoviral vector according to any one of claims 1 to 8 or obtainable by a method according to any one of claims 9 to
27.

20

29. A method of treating a human body comprising administering to a human body a recombinant adenoviral vector according to any one of claims 1 to 8, or a pharmaceutical composition according to claim 28.

25

30. A kit of parts comprising:

a) a complementing cell for producing a recombinant adenovirus vector comprising structural and non-structural elements of an adenovirus of a first
30 serotype, said cell harbouring an E1B-55K encoding sequence, or a functional part, derivative and/or

analogue thereof, derived from an adenovirus of a second serotype in expressible form; and

- b) on one or more replicable nucleic acid vectors all necessary adenoviral elements such as to allow
5 assembly of said recombinant adenovirus vector by said complementing cell, wherein said elements comprise at least some structural and non-structural elements from an adenovirus of said first serotype different from said second serotype and a sequence
10 encoding a functional E4-orf6 protein, or a functional part, derivative and/or analogue thereof, which is compatible with said expressible E1B-55K protein in said complementing cell.
- 15 31. A kit of parts according to claim 30, wherein said E4-orf6 encoding sequence is selected from the group consisting of:
1. an E4-orf6 encoding sequence derived from an adenovirus of said second serotype;
 - 20 2. an E4-orf6 encoding sequence derived from an adenovirus of a third serotype different from said first and second serotype;
 3. an E4-orf6 encoding sequence derived from an adenovirus of said first serotype comprising a deletion, mutation,
25 addition and/or substitution in one or more codons; and
 4. an E4-orf6 encoding sequence comprising a fusion
between a part of an E4-orf6 encoding sequence derived from a third serotype and a part of an E4-orf6 encoding
sequence derived from an adenovirus of said second
30 serotype, wherein said third serotype may be identical to-, or different from said first serotype.

Fig. 1




Fig. 2




Fig. 3




Fig. 4: Cloning steps for pUC.35-5E4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11

```

1  MTTSGVPFGMTLRPTRSRLSRRTTPYSRDRLPPFET-ETRATILEDHPLLP Ad5.E4-ORF6.PRO
1  MTTSGVPFGMTLRPTRSRLSRRTTPYSRDRLPPFET-ETRATILEDHPLLP Orf6 aaseq in Ad35.PR.5Orf6.PRO
1  M[S]G[S]N[S]M[T]R-L[R]A[R]S[T]S[C]A[R]H[P]Y[T]R[A]Q[L]P[R]C[E]E[N]E[T]R[A]S[M]T[E]D[H]P[L]L[P] Ad35.E4-ORF6.PRO

50  ECNTLTNHNVSIVRGLPCSVGFTLIQEWVVPWDNVLTRTELVLILKCMHV Ad5.E4-ORF6.PRO
50  ECNTLTNHNVSIVRGLPCSVGFTLIQEWVVPWDNVLTRTELVLILKCMHV Orf6 aaseq in Ad35.PR.5Orf6.PRO
50  [E]C[D]T[N]T[N]H[S]V[S]C[V]RGLPCS[A]S[F]T[V]L[Q]E[L]P[I]P[W]D[N]F[L]N[P]E[E]L[K]I[M]B[R]C[M]H[L] Ad35.E4-ORF6.PRO

100  CLCCANIDIMTSMNHGYESWALHCHCSPGSLQCIAGGQVLASWFRMVV Ad5.E4-ORF6.PRO
100  CLCCANIDIMTSMNHGYESWALHCHCSPGSLQCIAGGQVLASWFRMVV Orf6 aaseq in Ad35.PR.5Orf6.PRO
100  CLCCA[T]I[D]I[F]H[S]Q[V]I[H]G[R]E[N]W[V]L[H]C[H]C[N]Q[Q]G[S]L[Q]C[M]A[G]G[A]V[L]A[V]W[F]R[K]V[I] Ad35.E4-ORF6.PRO

150  DGAMFNQRFIWIYREVVNYNMPEKVMFMSSVFMGRGRHLIYLRLWYDGHVGS Ad5.E4-ORF6.PRO
150  DGAMFNQRFIWIYREVVNYNMPEKVMFMSSVFMGRGRHLIYLRLWYDGHVGS Orf6 aaseq in Ad35.PR.5Orf6.PRO
150  [L]G[C]M[I]N[Q]R[C]P[W]Y[R]Q[I]V[N]H[H]M[P]K[E]I[M]Y[V]G[S]V[F]L[R]E[R]H[L]I[Y]I[K]L[W]Y[D]G[H]A[G]A Ad35.E4-ORF6.PRO

200  VVPAMSEFGYSALHCGILNNIVVLCSSYCADLSEIRVRCCARRTRRLMLRA Ad5.E4-ORF6.PRO
200  VVPAMSEFGYSALHCGILNNIVVLCSSYCADLSEIRVRCCARRTRRLMLRA Orf6 aaseq in Ad35.PR.5Orf6.PRO
200  [I]I[S]D[N]S[P]G[H]S[A]E[N]Y[G]L[L]N[N]I[V]I[M]C[C]T[Y]C[K]D[L]S[E]I[R]M[R]C[C]A[H]R[T]R[H]L[M]L[R]A Ad35.E4-ORF6.PRO

250  VRI-AEETTA--MLYSCRTERRRQQFIRALLQHHRPILMHDYDS--T P M Ad5.E4-ORF6.PRO
250  VRI-AEETTA--MLYSCRTERRRQQFIRALLQHHRPILMHDYDS--T P M Orf6 aaseq in Ad35.PR.5Orf6.PRO
250  [I]K[I]M[L]Q[E]T[V]D[P]D[P]I[N]S[S]R[T]E[R]R[R]Q[R]L[L]V[G]L[M]R[H]N[R]P[I]P[F]S[D]Y[D]S[H]R[S]S[S]R Ad35.E4-ORF6.PRO

```

Decoration 'Decoration #1': Box residues that differ from Ad5.E4-ORF6.PRO.

Fig. 12

```

1  MTTSGVPFGMTLRPTRSRLSRRTPYSRDRLPPFEET-ETRA Ad5.E4-ORF6+7.PRO
1  MTTSGVPFGMTLRPTRSRLSRRTPYSRDRLPPFEET-ETRA Orf6+7 aaseq in Ad35.PR5Orf6.PRO
1  M[S]G[S][N-SIMTRLR][A]R[S]T[S]C[A][R][H][H]P[Y][T][R][A][Q][L][P][R][C][E][E][N]ETRA Ad35.E4-CRF6+7.pro

40  TILEDHPLLPECNILTMHNAWTSPSPPVKKQPQVGQQPVAAQ Ad5.E4-ORF6+7.PRO
40  TILEDHPLLPECNILTMHNAWTSPSPPVKKQPQVGQQPVAAQ Orf6+7 aaseq in Ad35.PR5Orf6.PRO
40  [S][M][T]E[D]H[P]L[L][P][D][C][D][T][M]T[M]H[S][K]T[V]I[Q]T[P]- - - - - E[S]H[P]Q Ad35.E4-CRF6+7.pro

80  QLDSDMNLSELPGEFINITDERLARQETVWNITPKNMSVT Ad5.E4-ORF6+7.PRO
80  QLDSDMNLSELPGEFINITDERLARQETVWNITPKNMSVT Orf6+7 aaseq in Ad35.PR5Orf6.PRO
71  QLD[C][E][S][A][L][K][D][Y][R][D][G][F][L][S]I[T]D[P]R[L]A[R][S]E[T]V[W]N[V][E][S][K][T]M[S][I][S] Ad35.E4-CRF6+7.pro

120  HDMMLFKASRGERTVYSVCWEGGGRLNTRVL Ad5.E4-ORF6+7.PRO
120  HDMMLFKASRGERTVYSV[K]WEGGG[X]I[T]R[I]L Orf6+7 aaseq in Ad35.PR5Orf6.PRO
111  [N][G][I][Q][M][F][H][A][V][R][G][E][R][L]VYSV[K]WEGGG[X]I[T]R[I]L Ad35.E4-CRF6+7.pro

```

Decoration 'Decoration #1': Box residues that differ from Ad5.E4-ORF6+7.PRO.

Fig. 13




Fig. 14






Fig. 15




462

Fig. 16




467

Fig. 17



462

FIG. 18: Generation of E1-deleted Ad35 vectors via double homologous recombination in PER.C6 cells



Transfection of three
Plasmids in PER.C6





Fig. 19



SEQUENCE LISTING

<110> CruceCell Holland B.V.
Vogels, Ronald
Bout, Abraham

<120> Means and methods for the production of adenovirus vectors

<130> 0075WO000ORD

<140>
<141> 2003-04-24

<160> 25

<170> PatentIn version 3.1

<210> 1
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 35FR

<400> 1
cgggatccac tttatttttag ttgtcgtctt c 31

<210> 2
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 35R4

<400> 2
cggaattctt aattaaggga aatgcaaadc tgtgagg 37

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 35psi-For

<400> 3
gtggtatttta tggcaggctg 20

<210> 4

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> primer DF35-1

<400> 4
cactcaccac ctccaattcc 20

<210> 5
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 5E4F

<400> 5
cgggatccgt ttgtgttatg tttcaacgtg 30

<210> 6
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 5E4R

<400> 6
gctggcgagc tcggcggagt aacttgatatg tg 32

<210> 7
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 355ITR

<400> 7
gatccggagc tcacaacgtc attttccac g 31

<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> primer 353ITR

<400> 8

aggaattcgc ggccgcatt● aaatc

25

<210> 9
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> primer E4-F1

<400> 9
agaggaacac attccccc

18

<210> 10
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> primer E4-R2

<400> 10
ggggagaaaag gactgtgtat tctgtcaaat gg

32

<210> 11
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> primer E4-F3

<400> 11
tttgacagaa tacacagtcc tttctccccg gctgg

35

<210> 12
<211> 33
<212> DNA
<213> Artificial Sequence

<220>
<223> primer E4-R4

<400> 12
acaaaatacg agaatagacta cgtccggcgt tcc

33

<210> 13
<211> 30
<212> DNA
<213> Artificial Sequence

<220>

<223> primer E4-F5

<400> 13

ggacgtagtc attctcgtat ttgtatagc

30

<210> 14

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> primer E4-R6

<400> 14

tcaccaacac agtggggg

18

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer NF-1

<400> 15

ccacaacccc cactactccc

20

<210> 16

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> primer NR-2

<400> 16

cgtctcttcc ctctcctctc c

21

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer NcoI-R

<400> 17

aggatcatcc gctgctgccc

20

<210> 18

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> primer NcoI-F

<400> 18

catcaggata gggcgggtgg

19

<210> 19

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 35E3for

<400> 19

aatgactaat gcaggtgcgc

20

<210> 20

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> primer 35E3rev

<400> 20

cgacgcgttg tagtcgttga gcttctag

28

<210> 21

<211> 294

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino acid sequence of the E4-orf6 protein of Adenovirus type 5

<400> 21

Met Thr Thr Ser Gly Val Pro Phe Gly Met Thr Leu Arg Pro Thr Arg
1 5 10 15

Ser Arg Leu Ser Arg Arg Thr Pro Tyr Ser Arg Asp Arg Leu Pro Pro
20 25 30

Phe Glu Thr Glu Thr Arg Ala Thr Ile Leu Glu Asp His Pro Leu Leu
35 40 45

Pro Glu Cys Asn Thr Leu Thr Met His Asn Val Ser Tyr Val Arg Gly
50 55 60

Leu Pro Cys Ser Val Gly Phe Thr Leu Ile Gln Glu Trp Val Val Pro
 65 70 75 80
 Trp Asp Met Val Leu Thr Arg Glu Glu Leu Val Ile Leu Arg Lys Cys
 85 90 95
 Met His Val Cys Leu Cys Cys Ala Asn Ile Asp Ile Met Thr Ser Met
 100 105 110
 Met Ile His Gly Tyr Glu Ser Trp Ala Leu His Cys His Cys Ser Ser
 115 120 125
 Pro Gly Ser Leu Gln Cys Ile Ala Gly Gly Gln Val Leu Ala Ser Trp
 130 135 140
 Phe Arg Met Val Val Asp Gly Ala Met Phe Asn Gln Arg Phe Ile Trp
 145 150 155 160
 Tyr Arg Glu Val Val Asn Tyr Asn Met Pro Lys Glu Val Met Phe Met
 165 170 175
 Ser Ser Val Phe Met Arg Gly Arg His Leu Ile Tyr Leu Arg Leu Trp
 180 185 190
 Tyr Asp Gly His Val Gly Ser Val Val Pro Ala Met Ser Phe Gly Tyr
 195 200 205
 Ser Ala Leu His Cys Gly Ile Leu Asn Asn Ile Val Val Leu Cys Cys
 210 215 220
 Ser Tyr Cys Ala Asp Leu Ser Glu Ile Arg Val Arg Cys Cys Ala Arg
 225 230 235 240
 Arg Thr Arg Arg Leu Met Leu Arg Ala Val Arg Ile Ile Ala Glu Glu
 245 250 255
 Thr Thr Ala Met Leu Tyr Ser Cys Arg Thr Glu Arg Arg Arg Gln Gln
 260 265 270
 Phe Ile Arg Ala Leu Leu Gln His His Arg Pro Ile Leu Met His Asp
 275 280 285
 Tyr Asp Ser Thr Pro Met
 290

<210> 22

<211> 299

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino acid sequence of the E4-orf6 protein of Adenovirus type 35

<400> 22

Met Ser Gly Ser Asn Ser Ile Met Thr Arg Leu Arg Ala Arg Ser Thr
1 5 10 15

Ser Cys Ala Arg His His Pro Tyr Thr Arg Ala Gln Leu Pro Arg Cys
20 25 30

Glu Glu Asn Glu Thr Arg Ala Ser Met Thr Glu Asp His Pro Leu Leu
35 40 45

Pro Asp Cys Asp Thr Met Thr Met His Ser Val Ser Cys Val Arg Gly
50 55 60

Leu Pro Cys Ser Ala Ser Phe Thr Val Leu Gln Glu Leu Pro Ile Pro
65 70 75 80

Trp Asp Met Phe Leu Asn Pro Glu Glu Leu Lys Ile Met Arg Arg Cys
85 90 95

Met His Leu Cys Leu Cys Cys Ala Thr Ile Asp Ile Phe His Ser Gln
100 105 110

Val Ile His Gly Arg Glu Asn Trp Val Leu His Cys His Cys Asn Gln
115 120 125

Gln Gly Ser Leu Gln Cys Met Ala Gly Gly Ala Val Leu Ala Val Trp
130 135 140

Phe Arg Lys Val Ile Leu Gly Cys Met Ile Asn Gln Arg Cys Pro Trp
145 150 155 160

Tyr Arg Gln Ile Val Asn Met His Met Pro Lys Glu Ile Met Tyr Val
165 170 175

Gly Ser Val Phe Leu Arg Arg Arg His Leu Ile Tyr Ile Lys Leu Trp
180 185 190

Tyr Asp Gly His Ala Gly Ala Ile Ile Ser Asp Met Ser Phe Gly Trp
195 200 205

Ser Ala Phe Asn Tyr Gly Leu Leu Asn Asn Ile Val Ile Met Cys Cys
210 215 220

Thr Tyr Cys Lys Asp Leu Ser Glu Ile Arg Met Arg Cys Cys Ala His
225 230 235 240

Arg Thr Arg Lys Leu Met Leu Arg Ala Ile Lys Ile Met Leu Gln Glu
245 250 255

Thr Val Asp Pro Asp Pro Ile Asn Ser Ser Arg Thr Glu Arg Arg Arg
 260 265 270

Gln Arg Leu Leu Val Gly Leu Met Arg His Asn Arg Pro Ile Pro Phe
 275 280 285

Ser Asp Tyr Asp Ser His Arg Ser Ser Ser Arg
 290 295

<210> 23

<211> 150

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino acid sequence of the E4-orf6+7 protein of Adenovirus type 5

<400> 23

Met Thr Thr Ser Gly Val Pro Phe Gly Met Thr Leu Arg Pro Thr Arg
 1 5 10 15

Ser Arg Leu Ser Arg Arg Thr Pro Tyr Ser Arg Asp Arg Leu Pro Pro
 20 25 30

Phe Glu Thr Glu Thr Arg Ala Thr Ile Leu Glu Asp His Pro Leu Leu
 35 40 45

Pro Glu Cys Asn Thr Leu Thr Met His Asn Ala Trp Thr Ser Pro Ser
 50 55 60

Pro Pro Val Lys Gln Pro Gln Val Gly Gln Gln Pro Val Ala Gln Gln
 65 70 75 80

Leu Asp Ser Asp Met Asn Leu Ser Glu Leu Pro Gly Glu Phe Ile Asn
 85 90 95

Ile Thr Asp Glu Arg Leu Ala Arg Gln Glu Thr Val Trp Asn Ile Thr
 100 105 110

Pro Lys Asn Met Ser Val Thr His Asp Met Met Leu Phe Lys Ala Ser
 115 120 125

Arg Gly Glu Arg Thr Val Tyr Ser Val Cys Trp Glu Gly Gly Gly Arg
 130 135 140

Leu Asn Thr Arg Val Leu
 145 150

<210> 24

<211> 150

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino acid sequence of the E4-orf6+7 fusion protein from Adenovirus type 5 and Adenovirus type 35

<400> 24

Met	Thr	Thr	Ser	Gly	Val	Pro	Phe	Gly	Met	Thr	Leu	Arg	Pro	Thr	Arg
1				5				10					15		

Ser	Arg	Leu	Ser	Arg	Arg	Thr	Pro	Tyr	Ser	Arg	Asp	Arg	Leu	Pro	Pro
		20						25					30		

Phe	Glu	Thr	Glu	Thr	Arg	Ala	Thr	Ile	Leu	Glu	Asp	His	Pro	Leu	Leu
		35					40					45			

Pro	Glu	Cys	Asn	Thr	Leu	Thr	Met	His	Asn	Ala	Trp	Thr	Ser	Pro	Ser
	50					55					60				

Pro	Pro	Val	Lys	Gln	Pro	Gln	Val	Gly	Gln	Gln	Pro	Val	Ala	Gln	Gln
65				70					75					80	

Leu	Asp	Ser	Asp	Met	Asn	Leu	Ser	Glu	Leu	Pro	Gly	Glu	Phe	Ile	Asn
				85					90					95	

Ile	Thr	Asp	Glu	Arg	Leu	Ala	Arg	Gln	Glu	Thr	Val	Trp	Asn	Ile	Thr
		100						105					110		

Pro	Lys	Asn	Met	Ser	Val	Thr	His	Asp	Met	Met	Leu	Phe	Lys	Ala	Ser
		115					120					125			

Arg	Gly	Glu	Arg	Thr	Val	Tyr	Ser	Val	Lys	Trp	Glu	Gly	Gly	Gly	Lys
	130					135					140				

Ile	Thr	Thr	Arg	Ile	Leu
145				150	

<210> 25

<211> 141

<212> PRT

<213> Artificial Sequence

<220>

<223> Amino acid sequence of the E4-crf6+7 protein of Adenovirus type 35

<400> 25

Met Ser Gly Ser Asn Ser Ile Met Thr Arg Leu Arg Ala Arg Ser Thr

1	5	10	15
Ser Cys Ala Arg His His Pro Tyr Thr Arg Ala Gln Leu Pro Arg Cys	20	25	30
Glu Glu Asn Glu Thr Arg Ala Ser Met Thr Glu Asp His Pro Leu Leu	35	40	45
Pro Asp Cys Asp Thr Met Thr Met His Ser Met Thr Val Ile Gln Thr	50	55	60
Pro Glu Ser His Pro Gln Gln Leu Asp Cys Glu Ser Ala Leu Lys Asp	65	70	75
Tyr Arg Asp Gly Phe Leu Ser Ile Thr Asp Pro Arg Leu Ala Arg Ser	85	90	95
Glu Thr Val Trp Asn Val Glu Ser Lys Thr Met Ser Ile Ser Asn Gly	100	105	110
Ile Gln Met Phe Lys Ala Val Arg Gly Glu Arg Leu Val Tyr Ser Val	115	120	125
Lys Trp Glu Gly Gly Gly Lys Ile Thr Thr Arg Ile Leu	130	135	140

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50125

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/86

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 46779 A (GREGORY RICHARD J ; ARMENTANO DONNA (US); GENZYME CORP (US); KAPLAN) 22 October 1998 (1998-10-22) abstract examples 1,2	1,8-10, 18,19, 23,29-32
A	WO 00 29573 A (CANJI INC) 25 May 2000 (2000-05-25) abstract page 18, line 22 -page 20, line 20	1,8-10, 18,19, 23,29-31
A	WO 98 46781 A (GREGORY RICHARD J ; MARSHALL JOHN (US); ARMENTANO DONNA (US); CHENG) 22 October 1998 (1998-10-22) examples -/--	1,8-10, 18,19, 29-31



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

9 September 2003

Date of mailing of the international search report

19/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50125

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 01563 A (MARCELLUS RICHARD C ;LAVOIE JOSEE N (CA); SHORE GORDON C (CA); TEO) 15 January 1998 (1998-01-15) abstract figure 10 examples ---	1,8-10, 18,19, 29-31
A	US 5 698 443 A (HENDERSON DANIEL ROBERT ET AL) 16 December 1997 (1997-12-16) the whole document ---	1,8,18, 19,29-31
A	WO 01 83797 A (AVIGEN INC ;COLOSI PETER (US)) 8 November 2001 (2001-11-08) abstract examples figures ---	1,8,18, 19,29-31
A	WO 99 61640 A (ANDERSON ROBERT JAMES ;PRENTICE HUGH GRANT (GB); UNIV LONDON (GB);) 2 December 1999 (1999-12-02) abstract examples ---	1,8,18, 19,29-31
Y	US 5 849 561 A (FALCK-PEDERSEN ERIK S) 15 December 1998 (1998-12-15) abstract examples ---	1,8
Y	WO 00 70071 A (HAVENGA MENZO JANS EMCO ;VOGELS RONALD (NL); BOUT ABRAHAM (NL); IN) 23 November 2000 (2000-11-23) abstract examples -----	1,8

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/50125

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 29 directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/50125

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9846779	A	22-10-1998	US 6100086 A	08-08-2000
			AU 727992 B2	04-01-2001
			AU 7133598 A	11-11-1998
			EP 0975785 A1	02-02-2000
			JP 2001524822 T	04-12-2001
			WO 9846779 A1	22-10-1998
			US 6358507 B1	19-03-2002
			US 2002028194 A1	07-03-2002
WO 0029573	A	25-05-2000	AU 2145300 A	05-06-2000
			WO 0029573 A2	25-05-2000
WO 9846781	A	22-10-1998	US 5981275 A	09-11-1999
			AU 7133698 A	11-11-1998
			EP 0975786 A2	02-02-2000
			JP 2001521390 T	06-11-2001
			WO 9846781 A2	22-10-1998
WO 9801563	A	15-01-1998	AU 731924 B2	05-04-2001
			AU 3860197 A	02-02-1998
			CA 2259152 A1	15-01-1998
			EP 0951553 A2	27-10-1999
			WO 9801563 A2	15-01-1998
			JP 2000515504 T	21-11-2000
US 5698443	A	16-12-1997	AU 729648 B2	08-02-2001
			AU 6393296 A	30-01-1997
			CA 2222457 A1	16-01-1997
			EP 0844888 A1	03-06-1998
			JP 11508770 T	03-08-1999
			WO 9701358 A1	16-01-1997
			US 2003152553 A1	14-08-2003
			US 2003044383 A1	06-03-2003
			US 5871726 A	16-02-1999
			US 6057299 A	02-05-2000
WO 0183797	A	08-11-2001	AU 5761101 A	12-11-2001
			WO 0183797 A2	08-11-2001
			US 2002052485 A1	02-05-2002
WO 9961640	A	02-12-1999	WO 9961640 A2	02-12-1999
US 5849561	A	15-12-1998	AU 743923 B2	07-02-2002
			AU 7584998 A	11-12-1998
			BR 9809846 A	20-06-2000
			EP 0988389 A1	29-03-2000
			HU 0003331 A2	28-02-2001
			JP 2001527420 T	25-12-2001
			NZ 500920 A	27-04-2001
			PL 336941 A1	17-07-2000
			SK 156799 A3	16-05-2000
			WO 9853087 A1	26-11-1998
WO 0070071	A	23-11-2000	AU 4954700 A	05-12-2000
			CA 2372655 A1	23-11-2000
			EP 1054064 A1	22-11-2000
			JP 2002543846 T	24-12-2002
			WO 0070071 A1	23-11-2000

THIS PAGE BLANK (USPTO)